Yes, there is an ongoing Ritalin shortage in the United States. The FDA lists multiple methylphenidate products (the active ingredient in Ritalin) with a “Current” shortage status, and as of spring 2026, at least eight manufacturers have active shortage listings. The problem is most severe for extended-release formulations, with many dosage strengths either on back order with no estimated return date or available only in limited quantities.
Which Formulations Are Affected
The shortage hits extended-release methylphenidate hardest. Several major generic manufacturers have reported significant supply gaps across nearly every common dosage strength. Reddy’s has its 18 mg, 27 mg, 36 mg, and 54 mg extended-release tablets on back order with no estimated release date. Rhodes, which makes Aptensio XR capsules, has all strengths on back order, also with no timeline for return. Teva’s extended-release capsules are listed as temporarily unavailable.
Other manufacturers are shipping limited amounts. Sandoz has its 10 mg, 20 mg, 30 mg, and 40 mg extended-release capsules on allocation, meaning pharmacies receive only a fraction of what they order. Trigen has all its extended-release tablets on allocation. Mallinckrodt has several strengths either on back order or on allocation, with some not expected back until the second quarter of 2026. Lannett’s 54 mg extended-release tablets are on back order with no return date, and its 36 mg tablets are in limited supply.
Immediate-release formulations have generally been easier to find, though availability varies by pharmacy and region. If you’re on an extended-release version and can’t fill it, your prescriber may be able to work with you on a temporary switch to an immediate-release schedule.
Why the Shortage Is Happening
Two forces are colliding: rising demand and constrained supply.
On the demand side, stimulant prescriptions in the U.S. grew 60% between 2012 and 2023, climbing from 50.4 million to 80.8 million dispensed prescriptions. Methylphenidate specifically went from about 14.9 million prescriptions in 2012 to 16.6 million in 2023. That growth accelerated after 2021, partly because a separate Adderall shortage pushed patients to switch. Prescription switching from amphetamine-based medications to methylphenidate hit its highest rate in 2023, adding unexpected pressure to an already tight supply chain.
On the supply side, methylphenidate is a Schedule II controlled substance, which means the DEA sets annual limits on how much manufacturers can produce. In 2025, the DEA raised the aggregate production quota from about 53.3 million grams to 58.3 million grams, a roughly 9% increase meant to support both current demand and new product development. But production quotas don’t translate instantly into pills on pharmacy shelves. Manufacturers need time to ramp up, and individual companies have faced their own manufacturing and distribution challenges that have kept supply below what’s needed.
When Supply Might Recover
There is no single resolution date. Different manufacturers have offered different timelines, and many have offered none at all. Mallinckrodt estimates some strengths returning in the second quarter of 2026. Certain extended-release capsule strengths have estimated return dates of late April 2026. But companies like Reddy’s and Rhodes have told pharmacists they simply cannot estimate when their products will be available again.
The DEA’s decision to increase production quotas is a step toward long-term stabilization, but quotas mainly support new manufacturing processes and expanded capacity. The practical effects will take months to materialize. For context, Australia’s drug regulator reported in mid-2025 that most methylphenidate shortages in that country had resolved, with supply continuing to stabilize. The U.S. market, which is far larger and governed by different regulatory constraints, has not reached that point yet.
What You Can Do Right Now
If your pharmacy can’t fill your prescription, start by talking to the pharmacist directly, not a pharmacy technician. Pharmacists at chain locations can often check inventory at other branches in the area and may know when their distributor expects the next shipment. If your chain pharmacy comes up empty, try independent or non-chain pharmacies. Smaller pharmacies sometimes have stock that larger chains don’t, and pharmacists at stores where you’re a regular customer may be more willing to share detailed availability information.
If you call around and come up empty, wait a few days and try again. Supply is arriving intermittently at many locations, so what’s unavailable on Monday might show up by Thursday. You can also contact the manufacturer directly. Some manufacturer websites provide availability information, and their customer service lines can sometimes help you locate stock in your area.
If a pharmacist seems hesitant to share stock information over the phone (a reasonable precaution with controlled substances), you can ask them to look up your name in the state’s prescription monitoring program to verify you have a legitimate prescription on file.
For patients who have gone weeks without being able to fill their prescription, the most productive step is a conversation with your prescriber. They may be able to switch you to a different formulation, a different manufacturer’s version, or in some cases a different medication class entirely while supply remains disrupted. Waiting until you’re completely out of medication to start this process makes gaps harder to avoid, so reach out as soon as you see signs your pharmacy is struggling to fill your prescription.